Who Optimizes SG&A Costs Better? AbbVie Inc. or Mesoblast Limited

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, AbbVie Inc. and Mesoblast Limited have taken different paths in optimizing these costs. From 2014 to 2023, AbbVie Inc. saw a significant increase in SG&A expenses, peaking in 2022 with a 98% rise from 2016. This reflects their aggressive expansion and marketing strategies. In contrast, Mesoblast Limited maintained a more stable SG&A cost structure, with expenses fluctuating modestly around a 10% range. This stability suggests a more conservative approach, focusing on core operations. The data reveals that while AbbVie Inc. invests heavily in growth, Mesoblast Limited prioritizes cost control. As we look to the future, the missing data for 2024 leaves room for speculation on how these strategies will evolve.